Generation of Red Blood Cells from Human Pluripotent Stem Cells—An Update
Cells · 05.06.2023 · 12 (11) · 1554
DOI: 10.3390/cells12111554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 05.06.2023. Verfasst von Shin-Jeong Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Pluripotent Stem Cells. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NHLBI, National Research Foundation of Korea (NRF) funded by the Korean government (MSIT).
Abstract (Originalsprache)
Red blood cell (RBC) transfusion is a lifesaving medical procedure that can treat patients with anemia and hemoglobin disorders. However, the shortage of blood supply and risks of transfusion-transmitted infection and immune incompatibility present a challenge for transfusion. The in vitro generation of RBCs or erythrocytes holds great promise for transfusion medicine and novel cell-based therapies. While hematopoietic stem cells and progenitors derived from peripheral blood, cord blood, and bone marrow can give rise to erythrocytes, the use of human pluripotent stem cells (hPSCs) has also provided an important opportunity to obtain erythrocytes. These hPSCs include both human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). As hESCs carry ethical and political controversies, hiPSCs can be a more universal source for RBC generation. In this review, we first discuss the key concepts and mechanisms of erythropoiesis. Thereafter, we summarize different methodologies to differentiate hPSCs into erythrocytes with an emphasis on the key features of human definitive erythroid lineage cells. Finally, we address the current limitations and future directions of clinical applications using hiPSC-derived erythrocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Research and Development Center, KarisBio Inc., 50-1 Yonsei-Ro, Avison Biomedical Research Center Room 525, Seodaemun-gu, Seoul 03722, Republic of Korea.
- Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
ORCID-Profile: Cholomi Jung
Förderung
- NHLBI NIH HHS
- NHLBI
- National Research Foundation of Korea (NRF) funded by the Korean government (MSIT)
- Parts/Materials Development Project in 2021
- Global Vaccine Leading Technology Center through the KHIDI
- Brain Korea 21 FOUR Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea
Zitieren
APA
Lee, S. J., Jung, C., Oh, J. E., Kim, S., Lee, S., Lee, J. Y., & Yoon, Y. S. (2023). Generation of Red Blood Cells from Human Pluripotent Stem Cells—An Update. Cells, 12(11), 1554. https://doi.org/10.3390/cells12111554
Vancouver
Lee SJ, Jung C, Oh JE, Kim S, Lee S, Lee JY, et al. Generation of Red Blood Cells from Human Pluripotent Stem Cells—An Update. Cells. 2023;12(11):1554. doi:10.3390/cells12111554
BibTeX
@article{Lee2023,
author = {Lee, Shin-Jeong and Jung, Cholomi and Oh, Jee Eun and Kim, Sangsung and Lee, Sangho and Lee, Ji Yoon and Yoon, Young-Sup},
title = {Generation of Red Blood Cells from Human Pluripotent Stem Cells—An Update},
journal = {Cells},
year = {2023},
volume = {12},
number = {11},
pages = {1554},
doi = {10.3390/cells12111554}
}
EUVIMED